A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Gefurulimab (Primary) ; Gefurulimab (Primary) ; Hyaluronidase
- Indications Myasthenia gravis; Proteinuria
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease
- 27 Apr 2023 Results presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 02 Feb 2022 Status changed from recruiting to completed.
- 15 Jun 2021 New trial record